CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2026-08-31
$250.9 million
NAVPS
As at 2026-09-21
$10.3828
MER (%)
As at 2026-03-31
0.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2026-08-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
7.42% 3.70% 11.99% 6.95% 22.06% 5.31% 1.48% - 5.63%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Matthew Strauss

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2026-08-31
Asset allocation (%)
  • US Equity 78.76
  • International Equity 17.03
  • Canadian Corporate Bonds 2.22
  • Cash and Equivalents 2.00
  • Other -0.01
Sector allocation (%)
  • Healthcare 91.81
  • Exchange Traded Fund 3.59
  • Fixed Income 2.22
  • Cash and Cash Equivalent 2.00
  • Other 0.38
Geographic allocation(%)
  • United States 78.29
  • Switzerland 7.09
  • United Kingdom 5.99
  • Netherlands 3.97
  • Canada 3.66
  • Europe 0.61
  • Other 0.38
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 9.04%
2. Johnson & Johnson Drugs 7.71%
3. UnitedHealth Group Inc Healthcare Services 7.09%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.44%
5. AbbVie Inc Drugs 6.38%
6. AstraZeneca PLC Drugs 5.99%
7. Danaher Corp Healthcare Equipment 5.26%
8. IQVIA Holdings Inc Drugs 4.81%
9. Stryker Corp Healthcare Equipment 4.80%
10. Merck & Co Inc Drugs 4.68%
11. DexCom Inc Healthcare Equipment 4.50%
12. Abbott Laboratories Healthcare Equipment 4.09%
13. argenx SE Drugs 3.97%
14. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.59%
15. Novartis AG Cl N Drugs 3.30%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.